Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01775800 · ClinicalTrials.gov registry record · NA

Treatment Modification to Reduce Symptom Burden in Hemodialysis

A NA study of End Stage Renal Disease, sponsored by The Rogosin Institute.

Completed
Registry status
NA
Development phase
16
Enrollment target
1
Study location

NCT01775800 is a NA study of End Stage Renal Disease that has completed, run by The Rogosin Institute. The registered enrollment target is 16 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01775800, a NA study of End Stage Renal Disease, has completed, sponsored by The Rogosin Institute.

COMPLETED
Registry status
NA
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing. This study seeks to reduce these symptoms by modifying the usual guidelines used to manage patients on hemodialysis. For example, rather than trying to keep serum phosphorus below 5.5, patients enrolled in this study may have treatment goals of less than 6.5, in order to reduce the number of pills they need to take and potentially reduce harmful side effects. Blood pressure and serum parathyroid hormone goals will also be modified, to see if these modifications help hemodialysis patients feel better.

Conditions Studied

Interventions

  • OTHER Treatment modification

Study Locations (1)

New York

  • The Rogosin Institute - New York

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2013-01
Est. Completion 2014-09
Phase NA

Sponsor

The Rogosin Institute

21 total trials

What the Registry Record Tells You About NCT01775800

The ClinicalTrials.gov registry entry for NCT01775800 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower). The listed sponsor is The Rogosin Institute, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Treatment modification is the first listed.

NCT01775800 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01775800 about?

NCT01775800 is a clinical study titled "Treatment Modification to Reduce Symptom Burden in Hemodialysis". Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing. This study seeks to reduce these symptoms by modifying the usual guidelines used to manage patients on hemodialysis. For example, rather than trying to keep serum phosph...

What is the current status of trial NCT01775800?

This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2013-01. Estimated completion is 2014-09.

What conditions does trial NCT01775800 study?

This clinical trial studies the following conditions: End Stage Renal Disease.

What interventions are being tested in trial NCT01775800?

The interventions under investigation include: Treatment modification (OTHER).

Who is sponsoring clinical trial NCT01775800?

This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01775800 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.